The FSH pen injector is a medical device used for administering
follicle-stimulating hormone (FSH) injections. FSH is a hormone that
helps regulate the menstrual cycle and stimulates the development of
eggs in the ovaries. The pen injector is a convenient and easy-to-use
device that allows patients to self-administer FSH injections at home.
The pen injector contains a pre-filled cartridge of FSH medication and a
needle that is inserted into the skin to deliver the medication. The
device is designed to be simple, safe, and accurate, and it can be
adjusted to deliver the correct dosage of medication. The FSH pen
injector is commonly used in fertility treatments for women who are
trying to conceive. Fsh Pen Injector,Fertility Injection Pen,Hormone Pen Injectors,Disposable Hgh Pen Injector Shanghai Enjosim Medical Technology Co., Ltd , https://www.enjosimmedical.com
New drugs for treating diabetes and obesity are being developed
Recently, a research report published in the international journal Nature, researchers from Monash University in Australia have clarified how most areas of major diabetes and obesity drug targets are activated. , related research or provide new hopes and ideas for later scientists to develop new treatments for treating diseases.
In the article, researchers identified a specific region in a key drug target called GLP-1R, which responds differently to natural hormones and potential drugs, which can lead to differential effects in the preclinical disease model; Researcher Denise Wootten said that research can help us change potential new drugs to capture beneficial differences in signaling pathways or better treat diseases.
Diabetes is a widespread chronic disease that causes organ failure and death. The disease affects approximately 10% of the population worldwide, and as the rate of obesity increases, the incidence of diabetes continues to rise. In Australia, the prevalence of diabetes among Aboriginal and Torres Strait Islander residents is also high. Common diabetes drugs such as exenatide and liraglutide often work through the GLP-1R receptor, a natural hormone that mimics receptors, and drugs that target GLP-1Rs are often approved for treatment. Obesity and is used in clinical trials to treat neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease.
However, so far, researchers have not clarified the specific process of interaction between these drugs and receptors; the researchers Sexton said that these drugs often show different mechanisms of action through the GLP-1R receptor, and these Differences can also lead to different therapeutic effects; the recent study found that the drug exenatide analogue, exendin-P5, is one of the agonists compared to the approved GLP-1R drug. In fact, it can interact with receptors in different ways.
Recently, researchers have found that exenatide-P5 can lower blood sugar levels in the body of diabetic animal models, and it may be able to better control the patient's blood glucose in a different mode of action to better treat patients; Of course, later researchers need to conduct more in-depth research to find new treatments for diabetes and obesity.
Next Article
Single cell separation technology